Skip to main content

Table 3 Presence of drug resistance associated mutations after 6 months on ART

From: Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV

ART follow up n = 79

Parameters

*Without Baseline protease DRMs n (%)

*With Baseline protease DRMs n (%)

With < 5 Baseline Gag drug resistance-associated mutations n (%)

With ≥ 5 Baseline Gag drug resistance-associated mutations n (%)

2NRTI + 1PI 28 (35.4)

Viral load

    

 < 50

4 (14.3)

17 (60.7)

4 (14.3)

17 (60.7)

50—200

3 (10.7)

1 (3.6)

2 (7.1)

 > 200

1 (3.6)

2 (7.1)

3 (7.9)

2NRTI + 1NNRTI 50 (63.3)

Viral load

    

 < 50

7 (14)

32 (64)

15 (30)

24 (48)

50—200

5 (10)

5 (10)

 > 200

4 (8)

1 (2)

3 (6)

  1. *Minor and major protease resistance mutations
  2. ART antiretroviral therapy, 2NRTI + PI two nucleoside reverse transcriptase inhibitors plus one protease inhibitor, 2NRTI + 1NNRTI two nucleoside reverse transcriptase inhibitors plus one non- two nucleoside reverse transcriptase inhibitor, DRMs drug resistance mutations, n number, % percentage